Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0192791 February 15, 2018
International Journal of Current Research Vol. 10, Issue, 04, pp.68266-68270, April, 2018
ISSN: 0975-833X
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Supplement Article
J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018 www.jaids.com
PLOS ONE | https://doi.org/10.1371/journal.pone.0203986 October 3, 2018
2018 Progress Report
PEPFAR Strategy for Accelerating HIV/AIDS Epidemic Control (2017-2020)
WHO TRS N°1012.
Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite... victims; and (v) a proposed process for validation and verification of countries reaching zero human deaths from rabies.
more
Key facts about major deadly diseases.This manual provides concise and up-to-date knowledge on 15 infectious diseases that have the potential to become international threats, and tips on how to respond to each of them.
You can download an interactive version directly at the website
http://www.who....int/emergencies/diseases/managing-epidemics/en/
more
Lancet Glob Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30407-8
Lancet Glob Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30409-1
Lancet Glob Health 2018, Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30387-5
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis... of 50 studies involving 12,000 patients from 25 countries, published yesterday in The Lancet, found that bedaquiline, linezolid, levofloxacin, and moxifloxacin were associated with greater treatment success and reduced mortality compared with the previously recommended first-line treatments, while clofazimine and carbapenem antibiotics were associated with significantly improved treatment outcomes (but not reduced mortality)
more
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework